Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual ) 11. Intrahepatic cholangiocarcinoma (closed to accrual ) 10. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual ) 8. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual ) 7. Adenocarcinoma with variants of small intestine (closed to accrual ) 6. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Epithelial tumors of major salivary glands (closed to accrual ) 3. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer, and squamous cell carcinoma of the head and neck ) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual ) 2.
#Spindle cell tumor trial#
This trial enrolls participants for the following cohorts based on condition: 1. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors.
0 kommentar(er)
